Lexicon Pharmaceuticals, Inc. (LXRX)
USD 0.4
(-5.2%)
USD 0.4
(-5.2%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.11 Million USD | 296.18% |
| 2022 | -288 Thousand USD | 99.47% |
| 2021 | -54.74 Million USD | -348.11% |
| 2020 | 22.06 Million USD | -93.08% |
| 2019 | 318.84 Million USD | 425.12% |
| 2018 | 60.71 Million USD | -31.34% |
| 2017 | 88.43 Million USD | 209.67% |
| 2016 | -80.63 Million USD | -331.53% |
| 2015 | 34.82 Million USD | 152.43% |
| 2014 | -66.42 Million USD | 24.05% |
| 2013 | -87.46 Million USD | -7.33% |
| 2012 | -81.48 Million USD | -4506.98% |
| 2011 | 1.84 Million USD | -62.33% |
| 2010 | 4.9 Million USD | -54.13% |
| 2009 | 10.7 Million USD | -66.89% |
| 2008 | 32.32 Million USD | -35.51% |
| 2007 | 50.11 Million USD | -31.15% |
| 2006 | 72.79 Million USD | -3.81% |
| 2005 | 75.68 Million USD | 22.58% |
| 2004 | 61.74 Million USD | 44.12% |
| 2003 | 42.83 Million USD | 21.7% |
| 2002 | 35.2 Million USD | -88.48% |
| 2001 | 305.57 Million USD | 1689.14% |
| 2000 | 17.07 Million USD | 154.92% |
| 1999 | 6.7 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 955 Thousand USD | 96.91% |
| 2024 Q2 | 1.34 Million USD | 55.08% |
| 2023 FY | 565 Thousand USD | 296.18% |
| 2023 Q3 | 155 Thousand USD | -49.84% |
| 2023 Q2 | 309 Thousand USD | 451.14% |
| 2023 Q1 | -88 Thousand USD | -17.33% |
| 2023 Q4 | 485 Thousand USD | 212.9% |
| 2022 Q3 | -69 Thousand USD | 4.17% |
| 2022 FY | -288 Thousand USD | 99.47% |
| 2022 Q1 | -72 Thousand USD | 99.56% |
| 2022 Q2 | -72 Thousand USD | 0.0% |
| 2022 Q4 | -75 Thousand USD | -8.7% |
| 2021 Q2 | -10.02 Million USD | 20.34% |
| 2021 FY | -54.74 Million USD | -348.11% |
| 2021 Q1 | -12.58 Million USD | -6422.68% |
| 2021 Q3 | -15.65 Million USD | -56.23% |
| 2021 Q4 | -16.48 Million USD | -5.27% |
| 2020 FY | 22.06 Million USD | -93.08% |
| 2020 Q4 | 198.99 Thousand USD | -96.68% |
| 2020 Q1 | 7.43 Million USD | -6.56% |
| 2020 Q2 | 8.43 Million USD | 13.51% |
| 2020 Q3 | 6 Million USD | -28.86% |
| 2019 Q3 | 293.87 Million USD | 3417.31% |
| 2019 Q1 | 8.66 Million USD | -47.5% |
| 2019 Q2 | 8.35 Million USD | -3.56% |
| 2019 Q4 | 7.95 Million USD | -97.29% |
| 2019 FY | 318.84 Million USD | 425.12% |
| 2018 Q3 | 6.3 Million USD | -51.18% |
| 2018 Q1 | 24.67 Million USD | -24.1% |
| 2018 FY | 60.71 Million USD | -31.34% |
| 2018 Q2 | 12.91 Million USD | -47.66% |
| 2018 Q4 | 16.5 Million USD | 161.73% |
| 2017 FY | 88.43 Million USD | 209.67% |
| 2017 Q4 | 32.5 Million USD | 23.41% |
| 2017 Q3 | 26.34 Million USD | 128.75% |
| 2017 Q2 | 11.51 Million USD | -36.26% |
| 2017 Q1 | 18.06 Million USD | 204.06% |
| 2016 Q4 | -17.36 Million USD | 30.03% |
| 2016 Q3 | -24.81 Million USD | 11.77% |
| 2016 Q1 | -24.5 Million USD | -125.31% |
| 2016 FY | -80.63 Million USD | -331.53% |
| 2016 Q2 | -28.12 Million USD | -14.77% |
| 2015 Q1 | -19.07 Million USD | -1414.47% |
| 2015 Q4 | 96.83 Million USD | 529.53% |
| 2015 Q3 | -22.54 Million USD | -10.55% |
| 2015 Q2 | -20.39 Million USD | -6.92% |
| 2015 FY | 34.82 Million USD | 152.43% |
| 2014 FY | -66.42 Million USD | 24.05% |
| 2014 Q4 | 1.45 Million USD | 106.13% |
| 2014 Q3 | -23.68 Million USD | -15.49% |
| 2014 Q2 | -20.51 Million USD | 13.37% |
| 2014 Q1 | -23.67 Million USD | -25.58% |
| 2013 FY | -87.46 Million USD | -7.33% |
| 2013 Q2 | -23.47 Million USD | -17.58% |
| 2013 Q1 | -19.96 Million USD | 3.88% |
| 2013 Q3 | -25.16 Million USD | -7.17% |
| 2013 Q4 | -18.85 Million USD | 25.07% |
| 2012 Q4 | -20.77 Million USD | -10.37% |
| 2012 FY | -81.48 Million USD | -4506.98% |
| 2012 Q2 | 199 Thousand USD | -33.67% |
| 2012 Q3 | -18.82 Million USD | -9557.29% |
| 2012 Q1 | 300 Thousand USD | -12.54% |
| 2011 Q4 | 343 Thousand USD | -3.38% |
| 2011 Q1 | 596 Thousand USD | -52.43% |
| 2011 Q2 | 555 Thousand USD | -6.88% |
| 2011 Q3 | 355 Thousand USD | -36.04% |
| 2011 FY | 1.84 Million USD | -62.33% |
| 2010 Q3 | 781 Thousand USD | -36.66% |
| 2010 FY | 4.9 Million USD | -54.13% |
| 2010 Q2 | 1.23 Million USD | -24.86% |
| 2010 Q1 | 1.64 Million USD | 16.22% |
| 2010 Q4 | 1.25 Million USD | 60.44% |
| 2009 Q3 | 2.13 Million USD | -28.71% |
| 2009 FY | 10.7 Million USD | -66.89% |
| 2009 Q2 | 2.98 Million USD | -28.29% |
| 2009 Q1 | 4.16 Million USD | -34.36% |
| 2009 Q4 | 1.41 Million USD | -33.74% |
| 2008 Q1 | 8.89 Million USD | -35.6% |
| 2008 Q3 | 7.51 Million USD | -21.47% |
| 2008 Q2 | 9.56 Million USD | 7.57% |
| 2008 FY | 32.32 Million USD | -35.51% |
| 2008 Q4 | 6.35 Million USD | -15.47% |
| 2007 FY | 50.11 Million USD | -31.15% |
| 2007 Q2 | 12.64 Million USD | -6.28% |
| 2007 Q3 | 10.16 Million USD | -19.62% |
| 2007 Q4 | 13.8 Million USD | 35.81% |
| 2007 Q1 | 13.49 Million USD | -16.0% |
| 2006 Q4 | 16.06 Million USD | -18.08% |
| 2006 Q1 | 20.95 Million USD | -38.17% |
| 2006 FY | 72.79 Million USD | -3.81% |
| 2006 Q2 | 16.16 Million USD | -22.86% |
| 2006 Q3 | 19.61 Million USD | 21.34% |
| 2005 FY | 75.68 Million USD | 22.58% |
| 2005 Q1 | 13.92 Million USD | -46.46% |
| 2005 Q2 | 13.89 Million USD | -0.19% |
| 2005 Q3 | 13.96 Million USD | 0.47% |
| 2005 Q4 | 33.89 Million USD | 142.74% |
| 2004 Q1 | 11.84 Million USD | -13.56% |
| 2004 FY | 61.74 Million USD | 44.12% |
| 2004 Q3 | 13.1 Million USD | 21.63% |
| 2004 Q4 | 26.01 Million USD | 98.42% |
| 2004 Q2 | 10.77 Million USD | -8.98% |
| 2003 FY | 42.83 Million USD | 21.7% |
| 2003 Q3 | 12.11 Million USD | 35.76% |
| 2003 Q4 | 13.7 Million USD | 13.12% |
| 2003 Q1 | 8.1 Million USD | -19.9% |
| 2003 Q2 | 8.92 Million USD | 10.05% |
| 2002 FY | 35.2 Million USD | -88.48% |
| 2002 Q4 | 10.12 Million USD | 26.29% |
| 2002 Q3 | 8.01 Million USD | -14.85% |
| 2002 Q2 | 9.41 Million USD | 22.92% |
| 2002 Q1 | 7.65 Million USD | -97.32% |
| 2001 Q1 | 3.31 Million USD | 122.83% |
| 2001 FY | 305.57 Million USD | 1689.14% |
| 2001 Q4 | 285.27 Million USD | 2014.25% |
| 2001 Q3 | 13.49 Million USD | 285.24% |
| 2001 Q2 | 3.5 Million USD | 5.78% |
| 2000 Q4 | -14.5 Million USD | -254.85% |
| 2000 Q1 | 15.8 Million USD | 0.0% |
| 2000 FY | 17.07 Million USD | 154.92% |
| 2000 Q3 | 9.36 Million USD | 45.96% |
| 2000 Q2 | 6.41 Million USD | -59.39% |
| 1999 FY | 6.7 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AbCellera Biologics Inc. | 38.02 Million USD | 97.057% |
| Alkermes plc | 1.37 Billion USD | 99.919% |
| Agenus Inc. | 139.61 Million USD | 99.199% |
| Aptorum Group Limited | -1.11 Million USD | 200.387% |
| Ardelyx, Inc. | 106.66 Million USD | 98.951% |
| Dyadic International, Inc. | 922.95 Thousand USD | -21.241% |
| Eton Pharmaceuticals, Inc. | 21.06 Million USD | 94.687% |
| Lantern Pharma Inc. | -174.84 Thousand USD | 740.003% |
| Inhibikase Therapeutics, Inc. | -13.35 Million USD | 108.377% |
| Novavax, Inc. | 639.93 Million USD | 99.825% |
| Janux Therapeutics, Inc. | -46.83 Million USD | 102.389% |
| Pyxis Oncology, Inc. | -2 Million USD | 155.95% |
| TransCode Therapeutics, Inc. | -516.74 Thousand USD | 316.547% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 94.124% |
| Outlook Therapeutics, Inc. | -44.18 Thousand USD | 2632.362% |
| Madrigal Pharmaceuticals, Inc. | -527 Thousand USD | 312.334% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Syros Pharmaceuticals, Inc. | -98.21 Million USD | 101.139% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -39.526% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 1464.634% |
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 99.173% |
| Clearside Biomedical, Inc. | 7.87 Million USD | 85.783% |
| C4 Therapeutics, Inc. | -96.95 Million USD | 101.154% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.926% |
| AlloVir, Inc. | -398 Thousand USD | 381.156% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 99.535% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -163.915% |
| Bicycle Therapeutics plc | -129.52 Million USD | 100.864% |
| BioXcel Therapeutics, Inc. | 120 Thousand USD | -832.5% |
| ChromaDex Corporation | 50.78 Million USD | 97.796% |
| Chimerix, Inc. | 324 Thousand USD | -245.37% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 103.59% |
| Caribou Biosciences, Inc. | -77.59 Million USD | 101.442% |
| CRISPR Therapeutics AG | 240.95 Million USD | 99.536% |
| Precision BioSciences, Inc. | 40.47 Million USD | 97.235% |
| Fate Therapeutics, Inc. | -98.16 Million USD | 101.14% |
| Fortress Biotech, Inc. | 57.85 Million USD | 98.066% |
| Fortress Biotech, Inc. | 57.85 Million USD | 98.066% |
| HOOKIPA Pharma Inc. | 16.57 Million USD | 93.25% |
| ImmuCell Corporation | 4.39 Million USD | 74.547% |
| IDEAYA Biosciences, Inc. | -106.12 Million USD | 101.054% |
| Immix Biopharma, Inc. | -5468.00 USD | 20564.521% |
| Incyte Corporation | 3.44 Billion USD | 99.967% |
| Innoviva, Inc. | 261.06 Million USD | 99.571% |
| IO Biotech, Inc. | -756 Thousand USD | 248.016% |
| Jaguar Health, Inc. | 7.72 Million USD | 85.513% |
| Keros Therapeutics, Inc. | -664 Thousand USD | 268.524% |
| Ligand Pharmaceuticals Incorporated | 119.75 Million USD | 99.066% |
| ContextLogic Inc. | 59 Million USD | 98.103% |
| MiMedx Group, Inc. | 266.84 Million USD | 99.581% |
| MEI Pharma, Inc. | 49.32 Million USD | 97.731% |
| NextCure, Inc. | -3.68 Million USD | 130.375% |
| Onconetix, Inc. | -1.12 Million USD | 199.276% |
| Oncternal Therapeutics, Inc. | -28.96 Million USD | 103.863% |
| Opthea Limited | 21.72 Thousand USD | -5051.934% |
| Psyence Biomedical Ltd. | -240.00 USD | 466350.0% |
| Vaxcyte, Inc. | -75 Million USD | 101.492% |
| PDS Biotechnology Corporation | -57.32 Thousand USD | 2051.994% |
| Precigen, Inc. | 106 Thousand USD | -955.66% |
| Pharming Group N.V. | 220.1 Million USD | 99.492% |
| Phathom Pharmaceuticals, Inc. | 515 Thousand USD | -117.282% |
| Pieris Pharmaceuticals, Inc. | 1 Million USD | -10.902% |
| PureTech Health plc | -1.6 Million USD | 169.807% |
| Rigel Pharmaceuticals, Inc. | 109.77 Million USD | 98.981% |
| Avidity Biosciences, Inc. | -181.4 Million USD | 100.617% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 102.469% |
| Sol-Gel Technologies Ltd. | -21.98 Million USD | 105.089% |
| Acelyrin, Inc. | -115 Thousand USD | 1073.043% |
| Salarius Pharmaceuticals, Inc. | -10.05 Thousand USD | 11233.221% |
| Summit Therapeutics Inc. | -2.05 Million USD | 154.585% |
| Sensei Biotherapeutics, Inc. | -571 Thousand USD | 295.972% |
| Senti Biosciences, Inc. | -2.68 Million USD | 141.707% |
| Stoke Therapeutics, Inc. | 4.05 Million USD | 72.377% |
| Elevation Oncology, Inc. | -39 Thousand USD | 2969.231% |
| Alaunos Therapeutics, Inc. | -4.79 Million USD | 123.322% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 128.386% |
| Entrada Therapeutics, Inc. | 29.12 Million USD | 96.158% |
| VistaGen Therapeutics, Inc. | 496 Thousand USD | -125.605% |
| Kintara Therapeutics, Inc. | -55 Thousand USD | 2134.545% |
| Wave Life Sciences Ltd. | 104.09 Million USD | 98.925% |
| Seer, Inc. | 7.02 Million USD | 84.076% |
| Verrica Pharmaceuticals Inc. | 4.37 Million USD | 74.44% |
| Aadi Bioscience, Inc. | 21.54 Million USD | 94.806% |
| ESSA Pharma Inc. | -118.49 Thousand USD | 1044.376% |
| GlycoMimetics, Inc. | -143.3 Thousand USD | 880.874% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Inhibrx Biosciences, Inc. | 609 Thousand USD | -83.744% |
| Akebia Therapeutics, Inc. | 120.47 Million USD | 99.071% |
| Catalyst Pharmaceuticals, Inc. | 313.67 Million USD | 99.643% |
| Longboard Pharmaceuticals, Inc. | -5000.00 USD | 22480.0% |
| Orchestra BioMed Holdings, Inc. | 2.57 Million USD | 56.527% |
| Alzamend Neuro, Inc. | -50.74 Thousand USD | 2305.361% |
| Sorrento Therapeutics, Inc. | 29.38 Million USD | 96.192% |
| TRACON Pharmaceuticals, Inc. | -232 Thousand USD | 582.328% |
| Viracta Therapeutics, Inc. | -492 Thousand USD | 327.439% |
| Rocket Pharmaceuticals, Inc. | -7.09 Million USD | 115.765% |
| Aptose Biosciences Inc. | -474.54 Thousand USD | 335.805% |
| ZyVersa Therapeutics, Inc. | -10.4 Thousand USD | 10859.615% |
| Soligenix, Inc. | 97.31 Thousand USD | -1049.921% |
| Century Therapeutics, Inc. | -10.8 Million USD | 110.352% |
| Kura Oncology, Inc. | -849 Thousand USD | 231.802% |
| TScan Therapeutics, Inc. | -67.1 Million USD | 101.668% |
| Intensity Therapeutics, Inc. | -147 Thousand USD | 861.224% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 99.03 Million USD | 98.87% |
| Autolus Therapeutics plc | -4.86 Million USD | 122.992% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 41.38 Million USD | 97.296% |
| Eterna Therapeutics Inc. | -168 Thousand USD | 766.071% |
| Adaptive Biotechnologies Corporation | 94.72 Million USD | 98.819% |
| GRI Bio, Inc. | 10.84 Million USD | 89.678% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | 55.945% |
| Tenaya Therapeutics, Inc. | -8.68 Million USD | 112.881% |
| IGM Biosciences, Inc. | -211.66 Million USD | 100.529% |
| INmune Bio, Inc. | 155 Thousand USD | -621.935% |
| Heron Therapeutics, Inc. | 61.93 Million USD | 98.193% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 174.288% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 272.564% |
| Entero Therapeutics, Inc. | -29.27 Thousand USD | 3922.505% |
| Milestone Pharmaceuticals Inc. | 402 Thousand USD | -178.358% |
| X4 Pharmaceuticals, Inc. | -1.99 Million USD | 156.062% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 457.508% |
| Coherus BioSciences, Inc. | 94.46 Million USD | 98.815% |
| Verastem, Inc. | -62 Thousand USD | 1904.839% |
| Abeona Therapeutics Inc. | 2.43 Million USD | 54.045% |
| Pliant Therapeutics, Inc. | -261 Thousand USD | 528.736% |
| Tonix Pharmaceuticals Holding Corp. | 3.02 Million USD | 63.033% |
| Histogen Inc. | 3.76 Million USD | 70.31% |
| Aprea Therapeutics, Inc. | 576.17 Thousand USD | -94.21% |
| Surrozen, Inc. | -27.23 Million USD | 104.109% |
| Organovo Holdings, Inc. | -5.38 Million USD | 120.765% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | -1.2 Million USD | 192.872% |
| Panbela Therapeutics, Inc. | -25.64 Million USD | 104.363% |
| CASI Pharmaceuticals, Inc. | 20.05 Million USD | 94.42% |
| Cadrenal Therapeutics, Inc. Common Stock | -1980.00 USD | 56615.152% |
| Centessa Pharmaceuticals plc | 6.06 Million USD | 81.554% |
| Hepion Pharmaceuticals, Inc. | -67.13 Thousand USD | 1766.89% |
| Arcturus Therapeutics Holdings Inc. | 154.79 Million USD | 99.277% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -667.49% |
| Apollomics, Inc. | 127 Thousand USD | -781.102% |
| Amarin Corporation plc | 165.54 Million USD | 99.324% |
| Mesoblast Limited | -9.81 Million USD | 111.401% |
| Turnstone Biologics Corp. | 16.5 Million USD | 93.221% |
| Kymera Therapeutics, Inc. | -110.48 Million USD | 101.013% |
| Synaptogenix, Inc. | -6347.00 USD | 17730.377% |
| Tiziana Life Sciences Ltd | -51 Thousand USD | 2294.118% |
| Aurinia Pharmaceuticals Inc. | 161.36 Million USD | 99.307% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 1.75 Billion USD | 99.936% |
| Better Therapeutics, Inc. | -2.72 Million USD | 141.004% |
| Nurix Therapeutics, Inc. | -112.16 Million USD | 100.998% |
| Apellis Pharmaceuticals, Inc. | 338.08 Million USD | 99.669% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 9908.906% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | -6.26 Million USD | 117.875% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 200.993% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 7.31 Million USD | 84.709% |
| Insmed Incorporated | 239.63 Million USD | 99.533% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 3.57 Million USD | 68.726% |
| OmniAb, Inc. | 14.66 Million USD | 92.371% |
| Alector, Inc. | -95.05 Million USD | 101.177% |
| Seres Therapeutics, Inc. | 125.62 Million USD | 99.109% |
| Checkpoint Therapeutics, Inc. | -43.46 Million USD | 102.575% |
| Zai Lab Limited | 170.9 Million USD | 99.345% |
| Revance Therapeutics, Inc. | 81.87 Million USD | 98.633% |
| Aura Biosciences, Inc. | -1.29 Million USD | 186.409% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -760.769% |
| Immunic, Inc. | -111 Thousand USD | 1108.108% |
| Tarsus Pharmaceuticals, Inc. | 15.85 Million USD | 92.942% |
| Veracyte, Inc. | 248.14 Million USD | 99.549% |
| InMed Pharmaceuticals Inc. | -6.98 Billion USD | 100.016% |
| FibroGen, Inc. | 128.9 Million USD | 99.132% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Adial Pharmaceuticals, Inc. | -564.00 USD | 198504.255% |
| Sonnet BioTherapeutics Holdings, Inc. | -11.66 Million USD | 109.591% |
| Jazz Pharmaceuticals plc | 3.39 Billion USD | 99.967% |
| Cyclacel Pharmaceuticals, Inc. | 389 Thousand USD | -187.661% |
| Amylyx Pharmaceuticals, Inc. | 355.34 Million USD | 99.685% |
| TG Therapeutics, Inc. | 219.1 Million USD | 99.489% |
| Galecto, Inc. | -830 Thousand USD | 234.819% |
| Calithera Biosciences, Inc. | -1.38 Million USD | 180.794% |
| Fortrea Holdings Inc. | 424 Million USD | 99.736% |
| KalVista Pharmaceuticals, Inc. | -86.16 Million USD | 101.299% |
| Aptevo Therapeutics Inc. | -567 Thousand USD | 297.354% |
| XBiotech Inc. | -1.74 Million USD | 164.163% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 200.993% |
| Lyra Therapeutics, Inc. | -46.47 Million USD | 102.408% |
| Foghorn Therapeutics Inc. | -75.53 Million USD | 101.481% |
| Y-mAbs Therapeutics, Inc. | 73.4 Million USD | 98.476% |
| Theravance Biopharma, Inc. | 16.8 Million USD | 93.34% |
| Ultragenyx Pharmaceutical Inc. | 389.04 Million USD | 99.712% |
| Metagenomi, Inc. Common Stock | -49.64 Million USD | 102.254% |
| Vaxxinity, Inc. | -2.23 Million USD | 150.09% |
| BioCryst Pharmaceuticals, Inc. | 326.75 Million USD | 99.658% |
| Gain Therapeutics, Inc. | -11.32 Million USD | 109.882% |
| Cartesian Therapeutics, Inc. | 24.45 Million USD | 95.424% |
| NexImmune, Inc. | -1.02 Million USD | 209.174% |
| Creative Medical Technology Holdings, Inc. | 5400.00 USD | -20622.222% |
| Marker Therapeutics, Inc. | -7.1 Million USD | 115.748% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.99% |
| Chemomab Therapeutics Ltd. | -66.82 Thousand USD | 1774.473% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | -3.55 Million USD | 131.512% |
| Ainos, Inc. | -253.73 Thousand USD | 541.015% |
| Pluri Inc. | 322 Thousand USD | -247.516% |
| Prothena Corporation plc | -129.2 Million USD | 100.866% |
| Adaptimmune Therapeutics plc | 50.42 Million USD | 97.781% |
| Celularity Inc. | 6.75 Million USD | 83.434% |
| Rallybio Corporation | -150 Thousand USD | 846.0% |
| Cue Biopharma, Inc. | -32.6 Million USD | 103.432% |
| MeiraGTx Holdings plc | 287 Thousand USD | -289.895% |
| Omeros Corporation | -69.77 Million USD | 101.604% |
| Humacyte, Inc. | -76.55 Million USD | 101.462% |
| Immunocore Holdings plc | 248.39 Million USD | 99.55% |
| Cocrystal Pharma, Inc. | -15.16 Million USD | 107.377% |
| Cidara Therapeutics, Inc. | 62.38 Million USD | 98.206% |
| Blueprint Medicines Corporation | 236.58 Million USD | 99.527% |
| CalciMedica, Inc. | -58 Thousand USD | 2029.31% |
| Cabaletta Bio, Inc. | -1.42 Million USD | 178.471% |
| Marinus Pharmaceuticals, Inc. | 29.05 Million USD | 96.149% |
| Scholar Rock Holding Corporation | -2.84 Million USD | 139.346% |
| Sana Biotechnology, Inc. | -30.86 Million USD | 103.625% |
| Pulmatrix, Inc. | -8.22 Million USD | 113.613% |
| Elicio Therapeutics, Inc. | -1.17 Million USD | 195.641% |
| Vigil Neuroscience, Inc. | -399 Thousand USD | 380.451% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 100.281% |
| Adlai Nortye Ltd. American Depositary Shares | 2.77 Million USD | 59.684% |
| Cytokinetics, Incorporated | -322.59 Million USD | 100.347% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | -29.799% |
| Protara Therapeutics, Inc. | -341 Thousand USD | 428.152% |
| Vor Biopharma Inc. | -3.49 Million USD | 132.045% |
| Roivant Sciences Ltd. | 109.23 Million USD | 98.976% |
| Evogene Ltd. | 1.39 Million USD | 20.014% |
| ProKidney Corp. | -3.16 Million USD | 135.311% |
| Applied Therapeutics, Inc. | -43.91 Million USD | 102.548% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 6.85 Million USD | 83.681% |
| CorMedix Inc. | -205.56 Thousand USD | 644.361% |
| BioLineRx Ltd. | 1.1 Million USD | -0.993% |
| Tango Therapeutics, Inc. | -78.67 Million USD | 101.422% |
| Galectin Therapeutics Inc. | -33 Thousand USD | 3490.909% |
| Atai Life Sciences N.V. | -5000.00 USD | 22480.0% |
| Renovaro Biosciences Inc. | -121.85 Thousand USD | 1018.274% |
| Aerovate Therapeutics, Inc. | -96 Thousand USD | 1265.625% |
| Zentalis Pharmaceuticals, Inc. | -1.38 Million USD | 180.562% |
| Sagimet Biosciences Inc. | 2 Million USD | 44.05% |
| MediciNova, Inc. | 979.7 Thousand USD | -14.218% |
| Praxis Precision Medicines, Inc. | -84.31 Million USD | 101.327% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 1283.438% |
| GeoVax Labs, Inc. | -20.72 Million USD | 105.4% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 99.542% |
| Biomea Fusion, Inc. | -4.2 Million USD | 126.637% |
| PTC Therapeutics, Inc. | 872.33 Million USD | 99.872% |
| Mereo BioPharma Group plc | 7.42 Million USD | 84.931% |
| Cullinan Oncology, Inc. | -310 Thousand USD | 460.968% |
| Syndax Pharmaceuticals, Inc. | -12 Thousand USD | 9425.0% |
| Absci Corporation | -41.84 Million USD | 102.674% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 22480.0% |
| 4D Molecular Therapeutics, Inc. | -76.37 Million USD | 101.465% |
| Dyne Therapeutics, Inc. | -2.46 Million USD | 145.469% |
| Kiniksa Pharmaceuticals, Ltd. | 213.73 Million USD | 99.476% |
| Ventyx Biosciences, Inc. | -941 Thousand USD | 218.916% |
| Allakos Inc. | -6.14 Million USD | 118.222% |
| Imunon, Inc. | -720 Thousand USD | 255.416% |
| Fulcrum Therapeutics, Inc. | -68.99 Million USD | 101.622% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 99.765% |
| BioAtla, Inc. | -103.73 Million USD | 101.079% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 9908.906% |
| Bio-Path Holdings, Inc. | -178 Thousand USD | 728.652% |
| Allogene Therapeutics, Inc. | -242.81 Million USD | 100.461% |
| Larimar Therapeutics, Inc. | -311 Thousand USD | 459.807% |
| XOMA Corporation | 3.86 Million USD | 71.018% |
| Kezar Life Sciences, Inc. | -70.08 Million USD | 101.597% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 92.436% |
| aTyr Pharma, Inc. | -2.38 Million USD | 146.859% |
| Aligos Therapeutics, Inc. | 12.46 Million USD | 91.019% |
| Akero Therapeutics, Inc. | -29 Thousand USD | 3958.621% |
| Viridian Therapeutics, Inc. | -1 Million USD | 211.012% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 13.00 USD | -8607592.308% |
| Akari Therapeutics, Plc | -4000.00 USD | 28075.0% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 99.824% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -474.707% |
| UroGen Pharma Ltd. | 73.35 Million USD | 98.474% |
| Sutro Biopharma, Inc. | -26.69 Million USD | 104.192% |
| ZIVO Bioscience, Inc. | 11.61 Thousand USD | -9538.243% |
| Orgenesis Inc. | -5.72 Million USD | 119.546% |
| Entera Bio Ltd. | -56 Thousand USD | 2098.214% |
| GH Research PLC | -315 Thousand USD | 455.238% |
| Lisata Therapeutics, Inc. | -189 Thousand USD | 692.063% |
| Reneo Pharmaceuticals, Inc. | -525 Thousand USD | 313.143% |
| Xencor, Inc. | -85.26 Million USD | 101.312% |
| 60 Degrees Pharmaceuticals, Inc. | -220.97 Thousand USD | 606.388% |
| Replimune Group, Inc. | -2.65 Million USD | 142.147% |
| Coeptis Therapeutics Holdings, Inc. | -1 Million USD | 211.762% |
| Vanda Pharmaceuticals Inc. | 177.84 Million USD | 99.371% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -474.707% |
| Portage Biotech Inc. | -54 Thousand USD | 2172.222% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 1283.438% |
| Olema Pharmaceuticals, Inc. | -377 Thousand USD | 396.817% |
| OncoCyte Corporation | 413 Thousand USD | -170.944% |
| Qualigen Therapeutics, Inc. | -4495.00 USD | 24994.327% |
| Processa Pharmaceuticals, Inc. | -222.00 USD | 504154.054% |
| Purple Biotech Ltd. | -196 Thousand USD | 670.918% |
| CollPlant Biotechnologies Ltd. | 8.96 Million USD | 87.522% |
| scPharmaceuticals Inc. | 9.78 Million USD | 88.561% |
| ProMIS Neurosciences, Inc. | -10.44 Million USD | 110.713% |
| HilleVax, Inc. | -2.15 Million USD | 151.902% |
| NeuroSense Therapeutics Ltd. | -97 Thousand USD | 1253.608% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | -15 Thousand USD | 7558.011% |
| Neumora Therapeutics, Inc. Common Stock | -668 Thousand USD | 267.515% |
| Atossa Therapeutics, Inc. | -23 Thousand USD | 4965.217% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | -7506.16 USD | 15007.756% |
| Savara Inc. | -44.26 Million USD | 102.528% |
| Curis, Inc. | 9.81 Million USD | 88.594% |
| Daré Bioscience, Inc. | 2.76 Million USD | 59.596% |
| Carmell Therapeutics Corporation | -124.78 Thousand USD | 996.721% |
| Titan Pharmaceuticals, Inc. | -1.72 Million USD | 164.719% |
| Achieve Life Sciences, Inc. | -228 Thousand USD | 590.789% |
| BeiGene, Ltd. | 2.07 Billion USD | 99.946% |
| Kiromic BioPharma, Inc. | -2.79 Million USD | 140.023% |
| Revolution Medicines, Inc. Warrant | -399.66 Million USD | 100.28% |
| Protagonist Therapeutics, Inc. | 56.68 Million USD | 98.026% |
| Erasca, Inc. | -3.73 Million USD | 129.984% |
| bluebird bio, Inc. | -4.03 Million USD | 127.767% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 4065.554% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.941% |
| DBV Technologies S.A. | 15.72 Million USD | 92.885% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 4065.554% |
| Moderna, Inc. | 2.15 Billion USD | 99.948% |
| Vincerx Pharma, Inc. | -915 Thousand USD | 222.295% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 86.023% |
| Molecular Templates, Inc. | 50.39 Million USD | 97.78% |
| Acrivon Therapeutics, Inc. Common Stock | -536 Thousand USD | 308.769% |
| Travere Therapeutics, Inc. | 133.78 Million USD | 99.164% |
| Monte Rosa Therapeutics, Inc. | -6.22 Million USD | 117.985% |
| Spruce Biosciences, Inc. | -39.34 Million USD | 102.844% |
| Celldex Therapeutics, Inc. | -111.12 Million USD | 101.007% |
| Cogent Biosciences, Inc. | -3.58 Million USD | 131.187% |
| MacroGenics, Inc. | 50.52 Million USD | 97.785% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | -6.09 Million USD | 118.35% |
| Prime Medicine, Inc. | -147.9 Million USD | 100.757% |
| Aditxt, Inc. | -111.66 Thousand USD | 1102.149% |
| Adagene Inc. | 18.11 Million USD | 93.822% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 488 Thousand USD | -129.303% |
| Maravai LifeSciences Holdings, Inc. | 140.2 Million USD | 99.202% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 157.83 Million USD | 99.291% |
| SciSparc Ltd. | 2.19 Million USD | 49.044% |
| Vericel Corporation | 135.57 Million USD | 99.175% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 4567.244% |
| Minerva Neurosciences, Inc. | -30.98 Thousand USD | 3711.775% |
| Generation Bio Co. | -73.91 Million USD | 101.514% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | -437 Thousand USD | 356.064% |
| Arcutis Biotherapeutics, Inc. | 54.61 Million USD | 97.951% |
| Invivyd, Inc. | -2.02 Million USD | 155.178% |
| Relay Therapeutics, Inc. | -300.84 Million USD | 100.372% |
| Quoin Pharmaceuticals, Ltd. | -103.43 Thousand USD | 1181.807% |
| Spero Therapeutics, Inc. | 96.36 Million USD | 98.839% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 98.28 Million USD | 98.862% |
| ADMA Biologics, Inc. | 88.21 Million USD | 98.732% |
| Clene Inc. | 533 Thousand USD | -109.944% |
| Capricor Therapeutics, Inc. | 24.1 Million USD | 95.359% |
| Boundless Bio, Inc. Common Stock | -957 Thousand USD | 216.928% |
| GeoVax Labs, Inc. | -20.72 Million USD | 105.4% |
| Recursion Pharmaceuticals, Inc. | 1.98 Million USD | 43.712% |
| Citius Pharmaceuticals, Inc. | -194.31 Thousand USD | 675.866% |
| Contineum Therapeutics, Inc. Class A Common Stock | 49.8 Million USD | 97.753% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | -7.09 Million USD | 115.778% |
| ALX Oncology Holdings Inc. | -836 Thousand USD | 233.852% |
| Vir Biotechnology, Inc. | 83.41 Million USD | 98.659% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -1430.529% |
| Ocular Therapeutix, Inc. | 53.16 Million USD | 97.895% |
| Verve Therapeutics, Inc. | -173.18 Million USD | 100.646% |
| Trevena, Inc. | 1.45 Million USD | 23.093% |
| Surrozen, Inc. | -27.23 Million USD | 104.109% |
| Tyra Biosciences, Inc. | -353 Thousand USD | 416.997% |
| Cingulate Inc. | -582.91 Thousand USD | 291.965% |
| Galmed Pharmaceuticals Ltd. | -31 Thousand USD | 3709.677% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 105.68% |
| Tenax Therapeutics, Inc. | -7570.00 USD | 14882.034% |
| Terns Pharmaceuticals, Inc. | -881 Thousand USD | 227.015% |
| ACADIA Pharmaceuticals Inc. | 680.7 Million USD | 99.836% |
| Connect Biopharma Holdings Limited | -988 Thousand USD | 213.259% |
| Clearmind Medicine Inc. | -56.34 Thousand USD | 2086.085% |
| Kronos Bio, Inc. | 1.37 Million USD | 18.44% |
| Bolt Biotherapeutics, Inc. | -53.66 Million USD | 102.085% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 483.219% |
| Statera Biopharma, Inc. | -488.31 Thousand USD | 329.156% |
| ImmunityBio, Inc. | -17.89 Million USD | 106.255% |
| Korro Bio, Inc. | -3.63 Million USD | 130.826% |
| Kineta, Inc. | 5.43 Million USD | 79.404% |
| BioVie Inc. | -229.37 Thousand USD | 587.843% |
| Codexis, Inc. | 57.33 Million USD | 98.048% |
| Celularity Inc. | 6.75 Million USD | 83.434% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | 72.116% |
| Celcuity Inc. | -142.77 Thousand USD | 883.767% |
| Virax Biolabs Group Limited | 50.59 Thousand USD | -2111.9% |
| Cibus, Inc. | 1.42 Million USD | 21.308% |
| Eledon Pharmaceuticals, Inc. | -374 Thousand USD | 399.198% |
| eFFECTOR Therapeutics, Inc. | -22.91 Million USD | 104.882% |
| IN8bio, Inc. | -2.5 Million USD | 144.742% |
| Kodiak Sciences Inc. | -25.94 Million USD | 104.313% |
| Annexon, Inc. | -3.26 Million USD | 134.252% |
| Adverum Biotechnologies, Inc. | -2.04 Million USD | 154.746% |
| Assembly Biosciences, Inc. | -41.73 Million USD | 102.681% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -74.844% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 99.856% |
| Eyenovia, Inc. | - USD | -Infinity% |
| Puma Biotechnology, Inc. | 172.95 Million USD | 99.353% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | -1.9 Million USD | 158.895% |
| Arcellx, Inc. | 108.27 Million USD | 98.967% |
| Cardiff Oncology, Inc. | -32.36 Million USD | 103.457% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 98.587% |
| Regulus Therapeutics Inc. | -21.15 Million USD | 105.29% |
| Moolec Science SA | -143.3 Thousand USD | 880.852% |
| Acumen Pharmaceuticals, Inc. | -42.31 Million USD | 102.644% |
| Geron Corporation | -123.5 Million USD | 100.906% |
| LAVA Therapeutics N.V. | 3.28 Million USD | 65.957% |
| Royalty Pharma plc | 1.79 Billion USD | 99.938% |
| Atea Pharmaceuticals, Inc. | -70.09 Million USD | 101.597% |
| Greenwich LifeSciences, Inc. | -3612.00 USD | 31080.066% |
| TFF Pharmaceuticals, Inc. | 231.39 Thousand USD | -383.597% |
| Mersana Therapeutics, Inc. | -111.41 Million USD | 101.004% |
| Humacyte, Inc. | -76.55 Million USD | 101.462% |
| Structure Therapeutics Inc. | -949.17 Thousand USD | 217.892% |
| 89bio, Inc. | -273 Thousand USD | 509.89% |
| PMV Pharmaceuticals, Inc. | -1.25 Million USD | 189.021% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | -848 Thousand USD | 231.958% |
| Trevi Therapeutics, Inc. | -123 Thousand USD | 1009.756% |
| Notable Labs, Ltd. | 113 Thousand USD | -890.265% |
| Liquidia Corporation | 14.6 Million USD | 92.336% |
| Mustang Bio, Inc. | -2.22 Million USD | 150.292% |
| Immunovant, Inc. | -231 Thousand USD | 584.416% |
| Quantum-Si incorporated | 488 Thousand USD | -129.303% |
| Arbutus Biopharma Corporation | -55.55 Million USD | 102.014% |
| DiaMedica Therapeutics Inc. | -30 Thousand USD | 3830.0% |
| Vera Therapeutics, Inc. | 1.86 Million USD | 39.903% |
| Acasti Pharma Inc. | -11 Thousand USD | 10272.727% |
| MiNK Therapeutics, Inc. | -204.61 Thousand USD | 646.875% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 272.564% |
| Xenon Pharmaceuticals Inc. | -167.51 Million USD | 100.668% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | 1.373% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Tempest Therapeutics, Inc. | -381 Thousand USD | 393.701% |
| Soleno Therapeutics, Inc. | -1.95 Million USD | 157.15% |
| PepGen Inc. | -1.18 Million USD | 194.51% |
| Moleculin Biotech, Inc. | -127 Thousand USD | 981.102% |
| United Therapeutics Corporation | 2.07 Billion USD | 99.946% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 104.887% |
| Solid Biosciences Inc. | -76.56 Million USD | 101.462% |
| BriaCell Therapeutics Corp. | -82.58 Thousand USD | 1455.0% |
| Immuneering Corporation | -764.13 Thousand USD | 246.44% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 66.26 Thousand USD | -1588.7% |
| Belite Bio, Inc | -399 Thousand USD | 380.451% |
| XOMA Corporation | 3.86 Million USD | 71.018% |
| ARS Pharmaceuticals, Inc. | -20.03 Million USD | 105.585% |
| Bionomics Limited | -434.44 Thousand USD | 357.568% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 204.19% |
| uniQure N.V. | 2.21 Million USD | 49.481% |
| Cassava Sciences, Inc. | -89.42 Million USD | 101.251% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | -92.06 Million USD | 101.215% |
| Forte Biosciences, Inc. | -9000.00 USD | 12533.333% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | -835 Thousand USD | 234.012% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | -437 Thousand USD | 356.064% |
| Altimmune, Inc. | -65.37 Million USD | 101.712% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 99.691% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 204.19% |
| Compugen Ltd. | 31.45 Million USD | 96.443% |
| Peak Bio, Inc. | 367.76 Thousand USD | -204.267% |
| Zevra Therapeutics, Inc. | 24.51 Million USD | 95.436% |
| Benitec Biopharma Inc. | 108 Thousand USD | -936.111% |
| Spyre Therapeutics, Inc. | -78 Thousand USD | 1534.615% |
| NKGen Biotech, Inc. Common Stock | -1.2 Million USD | 193.017% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | -1.82 Million USD | 161.416% |
| Aileron Therapeutics, Inc. | -119 Thousand USD | 1040.336% |
| NKGen Biotech, Inc. Warrants | -1.2 Million USD | 193.017% |
| Instil Bio, Inc. | -4.75 Million USD | 123.528% |
| argenx SE | 1.1 Billion USD | 99.899% |
| Immunome, Inc. | -8.9 Million USD | 112.563% |
| Compass Therapeutics, Inc. | -1.89 Million USD | 159.206% |
| Verona Pharma plc | -679.62 Thousand USD | 264.65% |
| enGene Holdings Inc. Warrants | -175 Thousand USD | 739.429% |
| Shattuck Labs, Inc. | -2.38 Million USD | 146.918% |
| CervoMed Inc. | -1.29 Million USD | 186.501% |
| LENZ Therapeutics, Inc. | -2.4 Million USD | 146.489% |
| Plus Therapeutics, Inc. | -4.77 Million USD | 123.425% |
| Dianthus Therapeutics, Inc. | 2.47 Million USD | 54.715% |
| Moolec Science SA | -143.3 Thousand USD | 880.852% |
| Enveric Biosciences, Inc. | -408.03 Thousand USD | 374.245% |
| Inovio Pharmaceuticals, Inc. | -2.67 Million USD | 141.886% |
| AnaptysBio, Inc. | 14.78 Million USD | 92.429% |
| Design Therapeutics, Inc. | -537 Thousand USD | 308.38% |
| Leap Therapeutics, Inc. | -427 Thousand USD | 362.061% |
| NeurAxis, Inc. | 2.15 Million USD | 48.115% |
| Seelos Therapeutics, Inc. | 2.14 Million USD | 47.856% |
| Lumos Pharma, Inc. | 2 Million USD | 44.245% |
| Achilles Therapeutics plc | -4.73 Million USD | 123.651% |
| enGene Holdings Inc. Common Stock | -175 Thousand USD | 739.429% |
| 180 Life Sciences Corp. | -105.67 Thousand USD | 1158.907% |
| Opiant Pharmaceuticals, Inc. | 31.65 Million USD | 96.465% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 862.1 Thousand USD | -29.799% |
| ORIC Pharmaceuticals, Inc. | -1.03 Million USD | 208.43% |
| CG Oncology, Inc. Common stock | -45.54 Million USD | 102.457% |
| Fractyl Health, Inc. Common Stock | 43 Thousand USD | -2502.326% |
| Rani Therapeutics Holdings, Inc. | -822 Thousand USD | 236.131% |
| MoonLake Immunotherapeutics | -13.15 Thousand USD | 8604.332% |
| Palisade Bio, Inc. | 246 Thousand USD | -354.878% |
| Tourmaline Bio, Inc. | -33 Thousand USD | 3490.909% |
| Beam Therapeutics Inc. | -59.67 Million USD | 101.875% |
| Neurogene Inc. | -3.26 Million USD | 134.304% |
| Mirum Pharmaceuticals, Inc. | 139.33 Million USD | 99.197% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | -3.69 Million USD | 130.309% |
| Sesen Bio, Inc. | 40 Million USD | 97.203% |
| Enliven Therapeutics, Inc. | -297 Thousand USD | 476.768% |
| Kiora Pharmaceuticals, Inc. | -4.02 Million USD | 127.787% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 111.698% |
| Taysha Gene Therapies, Inc. | 14.08 Million USD | 92.053% |
| Athira Pharma, Inc. | -969 Thousand USD | 215.48% |
| Vaccinex, Inc. | -16 Million USD | 106.992% |
| HCW Biologics Inc. | -574.82 Thousand USD | 294.668% |
| XOMA Corporation | 3.86 Million USD | 71.018% |
| Nektar Therapeutics | 53.47 Million USD | 97.908% |
| Arvinas, Inc. | 71.8 Million USD | 98.442% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | -83.46 Million USD | 101.341% |
| Omega Therapeutics, Inc. | -62.77 Million USD | 101.783% |
| Quince Therapeutics, Inc. | -322 Thousand USD | 447.516% |
| Rezolute, Inc. | -36 Thousand USD | 3208.333% |
| Clene Inc. | 533 Thousand USD | -109.944% |
| Indaptus Therapeutics, Inc. | -1284.00 USD | 87249.533% |
| BeyondSpring Inc. | 1.75 Million USD | 36.094% |
| Synlogic, Inc. | -1.92 Million USD | 158.16% |
| Allarity Therapeutics, Inc. | -37 Thousand USD | 3124.324% |
| Phio Pharmaceuticals Corp. | -6.33 Million USD | 117.672% |
| Peak Bio, Inc. | 367.76 Thousand USD | -204.267% |
| Werewolf Therapeutics, Inc. | -18.96 Million USD | 105.901% |
| Krystal Biotech, Inc. | 47.6 Million USD | 97.649% |
| Karyopharm Therapeutics Inc. | 141.09 Million USD | 99.207% |
| SpringWorks Therapeutics, Inc. | 5.02 Million USD | 77.731% |
| Lipella Pharmaceuticals Inc. | -2.58 Million USD | 143.218% |
| MannKind Corporation | 136.19 Million USD | 99.178% |
| Ikena Oncology, Inc. | -50.49 Million USD | 102.216% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 108.81 Million USD | 98.972% |
| Gossamer Bio, Inc. | -4.38 Million USD | 125.519% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | -252 Thousand USD | 544.048% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 22480.0% |
| Legend Biotech Corporation | 140.92 Million USD | 99.206% |
| Mural Oncology plc | -2.56 Million USD | 143.592% |
| Biora Therapeutics, Inc. | -551 Thousand USD | 303.085% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | -100 Thousand USD | 1219.0% |
| Champions Oncology, Inc. | 20.75 Million USD | 94.608% |
| REGENXBIO Inc. | 53.02 Million USD | 97.89% |
| Ensysce Biosciences, Inc. | -5.35 Million USD | 120.889% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | -192.37 Thousand USD | 681.676% |
| Edgewise Therapeutics, Inc. | -1.73 Million USD | 164.607% |
| Vaxart, Inc. | -60.76 Million USD | 101.842% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -262.78 Thousand USD | 525.831% |
| Cellectis S.A. | 18 Thousand USD | -6116.667% |
| Longeveron Inc. | 221 Thousand USD | -406.335% |
| Repare Therapeutics Inc. | -80.07 Million USD | 101.398% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.898% |
| Inozyme Pharma, Inc. | -1.29 Million USD | 186.476% |
| Revolution Medicines, Inc. | -399.66 Million USD | 100.28% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | -35 Thousand USD | 3297.143% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 49 Thousand USD | -2183.673% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.987% |
| Denali Therapeutics Inc. | -93.34 Million USD | 101.199% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 4567.244% |
| Veru Inc. | 7.56 Million USD | 85.21% |
| Corvus Pharmaceuticals, Inc. | -151 Thousand USD | 841.06% |
| Cingulate Inc. | -582.91 Thousand USD | 291.965% |
| Passage Bio, Inc. | -3.72 Million USD | 130.073% |
| Context Therapeutics Inc. | -12.04 Thousand USD | 9390.933% |
| Exicure, Inc. | -1.42 Million USD | 178.637% |
| Day One Biopharmaceuticals, Inc. | -383 Thousand USD | 392.167% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | 58.602% |
| Scinai Immunotherapeutics Ltd. | -512.67 Thousand USD | 318.267% |
| Rhythm Pharmaceuticals, Inc. | 68.12 Million USD | 98.357% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | -149.6 Thousand USD | 847.96% |
| Carisma Therapeutics, Inc. | -59.2 Million USD | 101.89% |
| Unicycive Therapeutics, Inc. | 391 Thousand USD | -186.189% |
| OmniAb, Inc. | 14.66 Million USD | 92.371% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 19.99 Million USD | 94.403% |
| Lipocine Inc. | -2.85 Million USD | 139.252% |
| Lexeo Therapeutics, Inc. Common Stock | -1.84 Million USD | 160.716% |
| Nautilus Biotechnology, Inc. | -5.7 Million USD | 119.614% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 174.288% |
| G1 Therapeutics, Inc. | 75.31 Million USD | 98.514% |
| Bellerophon Therapeutics, Inc. | -65 Thousand USD | 1821.538% |
| Sage Therapeutics, Inc. | 84.29 Million USD | 98.673% |
| Ocugen, Inc. | -33.53 Million USD | 103.337% |
| Mind Medicine (MindMed) Inc. | -3.16 Million USD | 135.389% |
| Q32 Bio Inc. | 578 Thousand USD | -93.599% |
| Brainstorm Cell Therapeutics Inc. | -265 Thousand USD | 522.264% |
| Alumis Inc. Common Stock | -1.28 Million USD | 187.15% |
| Equillium, Inc. | 35.95 Million USD | 96.888% |
| Kyverna Therapeutics, Inc. | -1.7 Million USD | 165.554% |
| Coya Therapeutics, Inc. | 500.67 Thousand USD | -123.496% |
| CNS Pharmaceuticals, Inc. | -4134.00 USD | 27168.215% |
| Galera Therapeutics, Inc. | -259 Thousand USD | 532.046% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Comera Life Sciences Holdings, Inc. | 422.71 Thousand USD | -164.719% |
| Dominari Holdings Inc. | 2.03 Million USD | 45.12% |
| Edesa Biotech, Inc. | -183.47 Thousand USD | 709.906% |
| vTv Therapeutics Inc. | -13.59 Million USD | 108.231% |
| Bio-Techne Corporation | 773.07 Million USD | 99.855% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 93.539% |
| Harmony Biosciences Holdings, Inc. | 460.78 Million USD | 99.757% |
| Prelude Therapeutics Incorporated | -1.16 Million USD | 195.723% |
| Candel Therapeutics, Inc. | -23.98 Million USD | 104.666% |
| iTeos Therapeutics, Inc. | 11.69 Million USD | 90.433% |
| Nkarta, Inc. | -5.86 Million USD | 119.066% |
| BioCardia, Inc. | -7.24 Million USD | 115.437% |
| Iterum Therapeutics plc | -1.75 Million USD | 163.943% |